Business Context and Reporting Period
This Form 8-K filing by Dare Bioscience, Inc. (DARE) is dated June 25, 2025, reporting an event that occurred on June 24, 2025. The filing addresses the company's ongoing compliance status with The Nasdaq Stock Market LLC regarding listing requirements.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance thresholds rather than operational financial performance.
- Stockholders' Equity Requirement: $2.5 million (Nasdaq Listing Rule 5550(b)(1)).
- Minimum Market Value of Listed Securities (MVLS): $35.0 million (Nasdaq Listing Rule 5550(b)(2)).
- Compliance Status: The company has been non-compliant with Nasdaq Listing Rule 5550(b) since August 2024.
Material Changes and Events
On June 24, 2025, the Nasdaq Hearings Panel amended its previous decision and approved Dare Bioscience's modified multi-step plan to regain compliance. Key details include:
- Plan Approval: The Panel approved a plan to demonstrate compliance with either the Stockholders' Equity Rule or the Minimum MVLS Rule.
- Deadlines: The company must demonstrate compliance by July 31, 2025. The conditional continued listing period remains in effect until August 12, 2025.
- Reporting Obligations: If compliance is achieved via the MVLS Rule, the company must publicly disclose transactions undertaken to increase equity and provide updated income projections for the next 12 months.
Outlook, Risks, and Contingencies
Management has issued no assurances that the Plan will be successfully executed or that compliance will be met by the July 31 or August 12, 2025 deadlines.
- Delisting Risk: Failure to execute the Plan to the Panel's satisfaction may result in a decision to delist common stock and suspend trading on Nasdaq prior to August 12, 2025.
- Panel Discretion: The Panel reserved the right to reconsider the extension terms based on any new events or conditions that make continued listing inadvisable.
- Capital Raising: The company faces risks related to its ability to raise additional capital to increase stockholders' equity.
Investor Verification Checklist
- Verify the company's current stockholders' equity and market value of listed securities against the $2.5 million and $35.0 million thresholds, respectively.
- Monitor public disclosures for any fundraising transactions or equity increases reported before the July 31, 2025 deadline.
- Review the company's updated income projections for the next 12 months once disclosed.
- Track any further communications from the Nasdaq Hearings Panel regarding the status of the conditional listing.